PERRIGO Co plc
For the period ended Mar 28, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 28, 2026 · Filed May 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Earnings per Share and Shareholders' Equity
Note 12
NOTE 12 -EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY
Earnings per Share
A reconciliation of the numerators and denominators used in our basic and diluted earnings per share (“EPS”) calculation is as follows (in millions):
| Three Months Ended | ||
|---|---|---|
| March 28, 2026 | March 29, 2025 | |
| Numerator: | ||
| Income (loss) from continuing operations | $(389.8) | $0.1 |
| Loss from discontinued operations, net of tax | (8.7) | (6.5) |
| Net income (loss) | $(398.6) | $(6.4) |
| Denominator: | ||
| Weighted average shares outstanding for basic EPS | 138.7 | 137.7 |
| Dilutive effect of share-based awards(1) | — | — |
| Weighted average shares outstanding for diluted EPS | 138.7 | 137.7 |
(1) In the period of a net loss, diluted shares equal basic shares.
Shareholders' Equity
Our common stock consists of ordinary shares of Perrigo Company plc, a public limited company incorporated under the laws of Ireland.
Our common equity has traded on the New York Stock Exchange under the symbol PRGO since June 6, 2013. Prior to that, our common equity traded on the Nasdaq Global Select Market under the same symbol. Our common equity was also traded on the Tel Aviv Stock Exchange (“TASE”) under the same symbol between March 16, 2005 and February 23, 2022, when we voluntarily delisted from trading in connection with the Rx business divestiture.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.